EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes

Panagiotis Stachteas, Dimitrios Patoulias, Djordje S Popovic, Polyxeni Athanasiadou, Nikolaos Fragakis

touchREVIEWS in Endocrinology · 2024

DOI: 10.17925/ee.2024.20.1.6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift touchREVIEWS in Endocrinology, 2024. Verfasst von Panagiotis Stachteas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality worldwide. Currently, over 10.5% of the adult population has been diagnosed with T2D, and almost 12% of total health expenditure is spent exclusively on T2D management globally. Sodium-glucose cotransporter-2 inhibitors are a relatively new class of oral antidiabetic agents that act by inhibiting renal sodium and glucose reabsorption. Except for their glucose-l owering effects, they have been associated with a more significant weight loss and blood pressure reduction and a lower risk of hypoglycaemia than other commonly prescribed antidiabetic drugs. On 20 January 2023, bexagliflozin became the fifth orally administered sodium-glucose transporter 2 inhibitor to be approved by the US Food and Drug Administration for the treatment of T2D as an adjunct therapy to diet and exercise in the USA after dapagliflozin, canagliflozin, empagliflozin and ertugliflozin. This review aims to discuss the current evidence on the efficacy and safety of bexagliflozin, which provides an important alternative treatment option for patients with T2D.

Schlagwörter

Stichwörter der Autor:innen

Antidiabetic drugsdietexerciseglycated haemoglobinsodium-glucose transporter 2 inhibitorstreatmenttype 2 diabetes

Autor:innen und Institutionen

  • Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
  • Postgraduate Studies Program in Public Health, Laboratory of Primary Health Care, General Practice and Health Services Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Zitieren

APA

Stachteas, P., Patoulias, D., Popovic, D. S., Athanasiadou, P., & Fragakis, N. (2024). Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. touchREVIEWS in Endocrinology. https://doi.org/10.17925/ee.2024.20.1.6

Vancouver

Stachteas P, Patoulias D, Popovic DS, Athanasiadou P, Fragakis N. Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. touchREVIEWS in Endocrinology. 2024. doi:10.17925/ee.2024.20.1.6

BibTeX
@article{Stachteas2024,
  author = {Stachteas, Panagiotis and Patoulias, Dimitrios and Popovic, Djordje S and Athanasiadou, Polyxeni and Fragakis, Nikolaos},
  title = {Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes},
  journal = {touchREVIEWS in Endocrinology},
  year = {2024},
  doi = {10.17925/ee.2024.20.1.6}
}
Kostenlos starten →